Clive Stanway
Fondateur chez Stroma Biosciences Ltd.
Profil
Clive Stanway is the founder of Stroma Biosciences Ltd.
founded in 2020, where he holds the title of Director-Drug Discovery.
He is currently a Director at Atelerix Ltd.
since 2018 and an Advisor at 4BIO Ventures Management Ltd.
He previously held the position of Principal at Xenova Group Plc and Prolifix Ltd.
and was the Chief Scientific Officer at Cancer Research Technology Ltd.
Dr. Stanway holds a doctorate from Imperial College London and an undergraduate degree from The University of Nottingham.
Postes actifs de Clive Stanway
| Sociétés | Poste | Début |
|---|---|---|
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Consultant / Advisor | - |
Atelerix Ltd.
 Atelerix Ltd. Electronic Equipment/InstrumentsElectronic Technology Atelerix Ltd. engages in preserving the viability and functionality of cells at hypothermic temperatures. The company was founded on June 5, 2017 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 21/07/2018 |
Stroma Biosciences Ltd.
 Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Fondateur | 01/01/2020 |
Anciens postes connus de Clive Stanway
| Sociétés | Poste | Fin |
|---|---|---|
| Prolifix Ltd. | Corporate Officer/Principal | - |
Xenova Group Plc
 Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Corporate Officer/Principal | - |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Formation de Clive Stanway
| Imperial College London | Doctorate Degree |
| The University of Nottingham | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Cancer Research Technology Ltd.
Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Health Technology |
| Prolifix Ltd. | Commercial Services |
Xenova Group Plc
Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Commercial Services |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Finance |
Atelerix Ltd.
Atelerix Ltd. Electronic Equipment/InstrumentsElectronic Technology Atelerix Ltd. engages in preserving the viability and functionality of cells at hypothermic temperatures. The company was founded on June 5, 2017 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Commercial Services |
